Merck’s lung cancer treatment will get a speedy review by the FDA, but it ‘knows better than to go out and give false hope,’ TheStreet’s Jim Cramer said. Shares of Merck were higher in late morning trading Wednesday, after the company announced the U.S. Food and Drug Administration would make a decision by May 10 on its lung cancer treatment that combines the immune system-boosting drug Keytruda with chemotherapy.